C1739039||EGFR protein
C1171362||expression
C0178719||intracellular
C1514562||domain
C0003241||antibody
C1430988||PTEN
C0149782||squamous cell lung cancer
C3899317||EGFR-tyrosine kinase inhibitor therapy
C0035168||research
C0582103||examine
C3899317||EGFR-tyrosine kinase inhibitor
C3899317||EGFR-tyrosine kinase inhibitor
C0332154||treated
C0149782||squamous cell carcinoma of the lung
C0149782||squamous cell carcinoma of the lung
C0035363||retrospective study
C0149782||squamous cell carcinoma of the lung
C0684249||lung cancer
C0040300||tissue
C0034869||records
C3899317||EGFR-TKI treatment
C1739039||EGFR protein
C1171362||expression
C0684249||lung cancer
C0040300||tissue
C0021044||immunohistochemistry
C0003241||antibody
C0524637||recognizes
C0178719||intracellular
C1514562||domain
C1514562||intracellular domain
C1739039||EGFR
C1430988||PTEN
C1171362||expression
C0684249||lung cancer
C0040300||tissue
C0220825||evaluated
C0021044||immunohistochemistry
C3273085||PI3KCA gene amplification
C0442726||detected
C3179034||quantitative real-time polymerase chain reaction
C1517090||FGFR1 amplification
C0162789||fluorescent in situ hybridization
C1739039||EGFR
C1514562||intracellular domain
C1171362||expression
C1520224||Eastern Cooperative Oncology Group (ECOG) performance status (PS)
C0178874||progression
C3899317||EGFR-TKIs treatment
C1430988||PTEN
C1171362||expression
C1739039||EGFR
C1446409||positive
C1430988||PTEN
C1446409||positive
C1520224||ECOG PS
C1333602||better clinical outcomes
C1739039||EGFR
C0205160||negative
C1430988||PTEN
C0205160||negative
C1520224||ECOG PS
C0178874||progression
C1739039||EGFR
C1171362||expression
C1514562||intracellular domain
C0003241||antibody
C1430988||PTEN protein
C1171362||expression
C0149782||squamous cell carcinoma of the lung
C3899317||EGFR-TKI treatment